Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 357 clinical trials
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or

cancer
FGFR2
primary cancer
metastatic cancer
  • 154 views
  • 14 Dec, 2020
  • 155 locations
featured
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

  • 176 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

adenocarcinoma
erlotinib
  • 182 views
  • 24 Nov, 2020
  • 1 location
featured
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study

lung carcinoma
lung cancer
cancer
  • 28 views
  • 23 Nov, 2020
  • 1 location
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with

  • 147 views
  • 03 Jun, 2021
  • 263 locations
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel

  • 0 views
  • 23 Jun, 2021
  • 24 locations
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

(PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The dual primary hypotheses

  • 0 views
  • 23 Jun, 2021
  • 37 locations
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer Compared to Nab-paclitaxel+Gemcitabine Treatment

/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

  • 31 views
  • 12 Jun, 2021
  • 272 locations
Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients

The purpose of this study is: to compare the effectiveness between the new strategy of treatment (given cis-platinum plus gemcitabine-neoadjuvant chemotherapy followed by

cancer
adenocarcinoma
concurrent chemoradiation
carboplatin
squamous cell carcinoma
  • 12 views
  • 08 Nov, 2020
  • 1 location
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have …

pd-l1
measurable disease
carboplatin
transitional cell carcinoma
enfortumab vedotin
  • 5 views
  • 27 May, 2021
  • 77 locations